Nasjonalt Handlingsprogram med Retningslinjer for Diagnostikk, Behandling og Oppfølging av Lungekreft

Objectives

Norway’s national lung-cancer action programme provides consensus-based, evidence-informed guidance for diagnosis, treatment and follow-up, supporting high-quality and equitable public cancer services throughout the country. It was developed under the National Cancer Strategy 2006–2009 and addresses a major national health burden, as lung cancer is Norway’s leading cause of cancer death.[1][2][3]

• Strengthen timely, accurate and minimally burdensome diagnosis, pathological classification and tumour-node-metastasis staging, so that treatment intent can be determined as curative or palliative.[4][5][6]
• Establish integrated and predictable patient pathways without unnecessary non-medically justified delays in investigation, diagnosis, treatment or rehabilitation.[7]
• Provide stage-, histology-, molecular-status- and patient-fitness-based treatment for non-small-cell lung cancer, small-cell lung cancer, neuroendocrine tumours, malignant pleural mesothelioma, emergencies and palliative needs.[8][9][10][11][12]
• Prioritise potentially curative surgery, radiotherapy and combined treatment for appropriately selected patients, while provide symptom relief, life-prolonging treatment and supportive care where cure is not feasible.[13][14][15][16]
• Support prevention, smoking cessation, survivorship care, management of treatment effects, recurrence detection and identification of new primary lung tumours across the care pathway.[17][18][19][20]

Implementation

The programme combines national professional guidance with individually adapted multidisciplinary care. General practice coordinates local prevention, referral and longer-term support, while specialist services lead complex diagnosis, treatment selection, initial follow-up and high-risk interventions.[17]Standardised cancer pathways begin when a health enterprise receives a referral with well-founded cancer suspicion, and regional health authorities are responsible for implementing and following up pathway timeframes.[7]

• Use rapid referral and diagnostic pathways, including prompt chest radiography for concerning symptoms, contrast-enhanced computed tomography of the chest and upper abdomen, tissue confirmation, positron emission tomography-computed tomography and magnetic resonance imaging when clinically indicated.[21][22][23][24]
• Assess candidates for curative treatment through multidisciplinary thoracic teams involving respiratory medicine, oncology, radiology, nuclear medicine, pathology and thoracic surgery; evaluate operability using respiratory function, cardiac risk, performance status, tumour characteristics and comorbidity.[8][25]
• Apply normative maximum intervals of seven calendar days from referral receipt to first attendance, 21 days from first attendance to completed investigation and decision, and a further seven to 14 days from completed investigation to treatment start depending on treatment type.[4]
• Document reasons in the patient record when normative pathway timeframes are exceeded; these timeframes guide organisation and logistics but are not individual legal rights.[4]
• Concentrate specialised interventions in expert services where necessary, including interventional bronchoscopy and radical multimodal mesothelioma treatment.[26][27]
• Use structured pathology and molecular testing to support personalised treatment, including epidermal growth factor receptor mutation testing in non-squamous non-small-cell lung cancer and screening for anaplastic lymphoma kinase rearrangements.[28][29]Molecular pathology should be performed at least weekly, with a maximum reporting time of 10 working days.[30][31]
• Coordinate primary and specialist care during treatment through discharge-summary review, primary-care consultations, blood-count monitoring between chemotherapy cycles, management of adverse effects, welfare support and rapid referral when complications arise.[18][21][32]
• Conduct specialist follow-up after potentially curative treatment using scheduled clinical review and imaging, while informing patients about symptoms that should prompt renewed contact and reinforcing smoking cessation.[20]
• Develop, review and update recommendations through collaboration between the Norwegian Directorate of Health, the Norwegian Knowledge Centre for the Health Services, professional communities, regional health authorities, municipalities, user organisations and other relevant authorities.[33][34]
• Review the programme annually and update it when necessary; the Norwegian Lung Cancer Group notifies the Directorate of Health when changes are needed, and an editorial committee prepares updates for publication.[35]

Recommendations are knowledge-based advice rather than directly legally binding rules. Healthcare providers should document and justify substantial departures, while hospital owners and managers are expected to facilitate adherence.[36]Evidence development uses systematic appraisal, consultation and multidisciplinary input, although the recommendations themselves were not graded because cost-effectiveness, ethics and other considerations were not explicitly assessed.[1][37]

The programme contains clinical timeframes, laboratory turnaround requirements and patient-level assessment criteria, but does not set out a comprehensive national performance dashboard, routine reporting system, audit framework, quantified outcome targets or dedicated implementation budget.[4][30][35]New methods should be assessed through the national system for introducing new methods in specialist health services before adoption; they may increase costs or reduce costs elsewhere, but no specific financing allocations are provided.[35]

Monitoring & Evaluation

The guideline combines document-level review arrangements with clinical monitoring across diagnosis, treatment and follow-up. National guidance is reviewed annually and updated when necessary by an editorial committee involving the professional community, the Norwegian Knowledge Centre for Health Services and the Norwegian Directorate of Health.[38][35]Guidelines are advisory rather than directly legally binding, but substantial departures should be documented and justified.[36][33]

• Implement standardised cancer pathways under regional health authority responsibility, with documentation of reasons for deviation from normative pathway timeframes.[7][4]
• Apply maximum normative intervals of 7 calendar days from referral receipt to first assessment and 21 days from first attendance to completed investigation and decision; maximum referral-to-treatment intervals are 42 days for surgery, 35 days for medicinal treatment and 14 days for radiotherapy.[4]
• Record diagnostic findings needed for treatment decisions, including histopathology, tumour subtype, location, clinical tumour-node-metastasis stage, molecular results, comorbidity, organ function and performance status.[6][39][40][28]
• Use multidisciplinary teams to assess operability, curative options and complex staging, including teams spanning respiratory medicine, oncology, radiology, nuclear medicine, pathology and thoracic surgery.[8][39][25]
• Monitor diagnostic quality through documented bronchoscopy sampling sites and techniques, specimen adequacy, structured pathology reporting, and molecular-testing turnaround, with analysis at least weekly and a maximum response time of 10 working days.[41][30][31]
• Use PET-computed tomography results cautiously and confirm clinically consequential positive findings where feasible; the method has not demonstrated value for routine individual surveillance of recurrence after curative treatment or for routine treatment-response monitoring.[42][23]
• Review treatment using clinical and radiological progression, remission, toxicity, symptoms, performance status and treatment tolerance; early response to tyrosine kinase inhibitors and later-line treatment should be assessed after approximately four weeks.[9][43][44][45]
• Monitor haematological parameters during cytotoxic treatment, identify infection and febrile neutropenia, and assess acute and late treatment effects in both specialist and primary-care follow-up.[18][21][32][46]
• Conduct specialist follow-up after potentially curative treatment through history, examination and scheduled imaging at one month, six, 12, 18 and 24 months, followed by annual low-dose computed tomography in years three to five; avoid routine tumour-marker tests, PET-computed tomography and fluorescence bronchoscopy for follow-up.[20]
• Recognise that most recurrences occur within four years, while new primary lung tumours may arise later; use recurrence detection, new-primary detection, local control and survival as relevant clinical outcomes, although the optimal surveillance schedule remains uncertain.[47]

The material does not establish a comprehensive national performance dashboard, routine reporting system, population surveillance framework, audit timetable or quantified implementation indicators. Its accountability mechanisms principally comprise regional pathway responsibility, documentation of deviations, clinical-record requirements, multidisciplinary decision-making, transparent evidence appraisal, consultation and annual guideline review.[7][4][1][37][35]

Costing & Financing

The guideline contains very limited explicit financial information. It does not specify a national budget, funding allocation, financing source, resource-mobilisation plan, quantified funding gap or monetary implementation target for lung-cancer services.[1][2][35]New diagnostic and treatment methods may either increase costs or reduce costs elsewhere in the health service, and proposed methods are to be assessed through the national system for introducing new methods in specialist health services before adoption.[35]

• Assess screening against cost-effectiveness and societal cost-benefit, including resource use, follow-up needs, false-positive findings, over-diagnosis and over-investigation; no programme budget or eligible-population cost estimate is provided.[48][49][50]
• Recognise evidence that PET-computed tomography may be more accurate and potentially cost-saving than conventional computed-tomography staging, with the strongest cited cost-effectiveness evidence relating to staging of non-small-cell lung cancer.[42]
• Consider that intensive post-curative surveillance, especially computed-tomography-based follow-up, was more costly in earlier studies, while no monetary values or preferred cost-effective surveillance schedule are supplied.[47]
• Note that cost-effectiveness and cost-benefit were regarded as relevant considerations in guideline development but were not explicitly assessed when recommendations were graded.[1]
• Prefer carboplatin-vinorelbine partly because of its favourable price, although no drug price, budget impact or procurement arrangement is provided.[51][52]
• Recognise stated relative resource implications without quantified values: cisplatin-based treatment is more resource-intensive than carboplatin-based treatment, oral topotecan is relatively costly and more costly than ACO, and carboplatin-irinotecan has higher costs than the preferred extensive-stage small-cell lung cancer regimen.[53][54][55][56]
• Record that Montebello-senteret stays and travel are covered through HELFO apart from a small copayment; neither the copayment amount nor total public expenditure is specified.[57]
• Note that silicone airway stents are described as inexpensive, without a stated unit cost or currency.[58]

Although the guidance identifies resource-intensive requirements such as multidisciplinary teams, specialist centres, molecular pathology, PET-computed tomography, magnetic resonance imaging, complex surgery and radiotherapy, it provides no costing methodology, workforce model, capital plan or funding-gap estimate for their implementation.[12][59][60]